Several experimental studies have demonstrated a potential association between an exposure to inhalation agents and the neuropathogenesis of Alzheimer’s Disease (AD) as reflected by an increased production and aggregation of β-amyloid peptides (Aβ) as well as elevated levels of cerebrospinal fluid tau protein (29–32). The gene discussed is MAPT; the disease is Alzheimer disease.